VC Ophthalmology · Checked.be

Summary

Conclusion

the dossier summarised in one paragraph

The computed 12-month bankruptcy probability of VC Ophthalmology is 0.2% (very low). The 2025 annual accounts show equity of €3k and a net result of €157k. Equity is growing by ~112.6% per year across the filed fiscal years. Its solvency ranks better than 6% of 2209 sector peers (fiscal year 2025). The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.

Based on the State Gazette, CBE and 5 annual accounts.

Signals

2 signals · with evidence

Weak solvency vs sector

Solvency (equity / total assets) is in the sector's weakest quartile: better than 6% of 2209 sector peers (2025).

View the sector comparison

Consistently profitable

Positive net result in the two most recent financial years (2024 and 2025).

View the result trend

Signals are derived from the filed annual accounts and the sector comparison. No composite score: each signal is separately verifiable at the source.

Filing behaviour

From the deposit records, complete market-wide

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 06-03-2026, 147 days ahead of the deadline. This speaks to administrative punctuality and says nothing about the financial position.

The next deadline is still running

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.

How we compute the deadline

The year end is derived from 5 filed financial years, each closing on 31-12. The statutory deadline is seven months after the close of the financial year (art. 3:10 par. 1 CAC, art. 3:47 par. 7 for ASBL and foundations). Applied to the financial year that closed on 31-12-2025, that is 31-07-2026.

Deadline per financial year

Year closed	Due by	Filed	Variance	Reference
31-12-2025	31-07-2026	06-03-2026	147 d early	2026-00051094
31-12-2024	31-07-2025	30-07-2025	1 d early	2025-00332584
31-12-2023	31-07-2024	26-06-2024	35 d early	2024-00172882
31-12-2022	31-07-2023	24-05-2023	68 d early	2023-00093350
31-12-2021	31-07-2022	08-08-2022	8 d late	2022-20277150

Source: the National Bank's deposit records. Those records are complete, including for years whose figures we have not read yet. Filing late covers nearly half the market and is therefore not scored; only not filing, being more than 90 days late and breaking a punctual record carry weight.

Trust signals

2 signals

More than 3 years active

Founded in 2021, past the statistically most fragile first 3 years.

No legal incidents

No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.

Administrative Flags

No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

Bankruptcy probability (12 mo)

Checked model v1 · free for everyone

0.2% Very low

0%0,5%1,5%4%10%≥25%

Lower-failure-rate sector −Young company +Annual accounts: healthy financial profile −

Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?

Financials

TurnoverNot published (abbreviated filing)

EBIT marginNot published (abbreviated filing)

Net result€157k-21.4%

Working capital€-12k

CSV export

Annual accounts & ratios

Source: NBB · 2025

Annual accounts filed on 06-03-2026 with the NBB · fiscal year 2025 · micro

Operating resultNet result

Trajectory (indicative)

Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.

growing Equity: growth of ~112.6%/year over 5 fiscal years, indicative, assuming unchanged policy.

Solid line = filed figures · dashed = extended trend · area = indicative range.

How do we compute this?

The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.

The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.

A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).

Sector comparison

Fiscal year 2025 · NACE 86, Human health · compared within the same schema type (micro schema)

Metric	This company	Sector median	Position in the sector
Solvency	0.5%	58.2%	better than 6% of 2209 sector peers
Net result	€157k	€60k	better than 85% of 2207 sector peers
Equity	€3k	€74k	better than 10% of 2209 sector peers
Gross operating margin	€223k	€96k	better than 83% of 2209 sector peers
Staff costs	€3k	€22k	higher than 28% of 359 sector peers

Median and position computed from NBB annual accounts filed by sector peers; own figures from the latest filed accounts.

Sector position over time

Percentile per fiscal year versus peers that filed figures, computed year by year (a year without enough peers is absent).

Solvency P6

Stable position over 2021-2025 · n=1833-6573

Net result P85

Improving position over 2021-2025 · n=1833-6567

Equity P10

Improving position over 2021-2025 · n=1833-6573

Gross operating margin P83

Improving position over 2021-2025 · n=1834-6575

Describes the position versus peers, not a forecast.

EBITDA

€219k

-18.2% 21-25

Net profit

€157k

-21.4% 21-25

Cash flow

€157k

-21.5% 21-25

Total assets

€519k

-8.7% 21-25

Equity

€3k

-99.3% 21-25

Working capital

€-12k

- 21-25

Staff costs

€3k

+76.5% 21-25

Income taxes

€55k

-13.0% 21-25

Dividends

€525k

- 21-25

Debt

€517k

+161.1% 21-25

Debt ≤ 1y

€386k

+853.1% 21-25

Debt > 1y

€131k

-16.8% 21-25

Current ratio

0.97

-90.7% 21-25

Quick ratio

0.97

-90.7% 21-25

Solvency

0.5%

-99.3% 21-25

Debt / equity

206.62

+38594.9% 21-25

ROE

6283.4%

+11556.7% 21-25

ROA

30.3%

-13.9% 21-25

Interest coverage

30.73

-37.7% 21-25

Figures by fiscal year

Highlight YoY changes (±10%)

Fiscal year	2025
Deposit	micro
Revenue	-
EBITDA	€219k
Net profit	€157k
Cash flow	€157k
Staff costs	€3k
Income taxes	€55k
Dividends	€525k
Total assets	€519k
Equity	€3k
Debt	€517k
of which ≤ 1y	€386k
of which > 1y	€131k
Working capital	€-12k
Employees (FTE)	-

Ratios (computed)

	2025
Current ratio	0.97
Quick ratio	0.97
Working capital ratio	-2.3%
Solvency	0.5%
Debt / equity	206.62
Long-term debt ratio	52.37
Interest coverage	30.73
Gross margin	-
Net margin	-
ROA	30.3%
ROE	6283.4%
EBITDA margin	-
Days sales outstanding	-
Days payable outstanding	-
Inventory turnover	-
Days inventory (DSI)	-

Balance-sheet composition 2025

Assets

Fixed assets €146k · 28.0% Current assets €374k · 72.0%

Equity & liabilities

Equity €3k · 0.5% Debt €517k · 99.5%

Full annual accounts

Filed balance sheet and income statement, exactly as deposited with the NBB.

Line item	Code	2025
Balance sheet, Assets
TOTAL ASSETS	20/58	€519k
Fixed assets	21/28	€146k
Financial fixed assets	28	€146k
Current assets	29/58	€374k
Amounts receivable within one year	40/41	€64k
Investments	50/53	€106k
Cash & bank	54/58	€136k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES	10/49	€519k
Equity	10/15	€3k
Contributions / capital	10/11	€3k
Reserves	13	€0
Accumulated profits (losses)	14	€0
Amounts payable	17/49	€517k
Amounts payable after one year	17	€131k
Amounts payable within one year	42/48	€386k
Trade debts payable within one year	44	€922
Income statement
Gross operating margin	9900	€223k
Operating result	9901	€219k
Financial income	75	€0
Financial charges	65	€7k
Result before taxes	9903	€212k
Income taxes	67/77	€55k
Net result for the period	9904	€157k
Result to be appropriated	9905	€157k

You're seeing the latest fiscal year only. Unlock 4 prior years (figures + ratios) with a paid plan. See plans →

Ratios computed by Checked.

Health barometer

FY 2025 · computed

45 / 100 Fair

050100

Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.

Unlock the full score breakdown, per-year score history and the indicative credit limit from Kantoor S.

See plans →

Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.

Structure & network

Locations & real estate

Registered office

on the map · from the address register

exact location from the address register On OpenStreetMap

Establishment units

1 location

VC Ophthalmology

Poederleesteenweg 42, 2460 KasterleeHandel in eigen onroerend goed

since 20212.320.760.236

Physical sites registered in the Crossroads Bank for Enterprises (CBE).

Parcels1

Ground area464 m²

Real-estate footprint

Source: CBE × cadastre · address linking

Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.

Flanders 1 (100%)

Parcel (capakey)	Region	Area	Buildings	Height / fl.
13018F0357/00E000	Flanders	464 m²	-	-

Methodology

via registered seat: 1

1 of 1 parcels with an exact address match; the rest are indicative.

Linked through address data, this is not proof of ownership.

Publications

Lifecycle & Insolvency Signals

No insolvency signals in the Belgian State Gazette

Belgisch Staatsblad · acts

1 acts

Address history · 1

08-08-2025

Registered-office move

All acts · 1 updated 1 year ago

2025

08-08-2025 Registered office moved from KASTERLEE to LICHTAART Registered-office change

2460 KASTERLEE, Netestraat 25 → 2460 LICHTAART, Poederleesteenweg 42

Original publication ↗

Analysis

Snowflake analysis

financial profile on 5 axes

62 / 100

Strong profile, led by profitability.

All 5 axes are computed from data Checked has read.

Health 45

Profitability 100

Solvency 11

Growth 58

Stability 94

Ask AI about this company

Checked AI

Soon: ask questions about this dossier, risks, curator, sector comparison, answered from the official data on this page.

TryWhat are the main risks?Any recent red flags?Compare to sector peers

Coming soon

AI due-diligence brief

Checked AI

Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.

Coming soon

The brief is drafted by our AI model at Anthropic in the US, from this dossier's public data. Nothing that identifies you is sent along and we do not keep the brief. Indicative, not legal or investment advice. How it works